Big Biotech Emerges as Late-Stage Licensee
The sheer size of today's Big Pharmas has created a problem when it comes to licensing late-stage products; many of those available simply don't have large enough revenue projections to significantly contribute to the Big Pharmas' earnings. But larger biotechs, which don't necessarily need blockbusters to grow earnings, seem to have begun to fill the gap.
You may also be interested in...
Are biotechs abandoning drug discovery-based business models in favor of in-licensing-based development and marketing strategies? In both annual count and, more dramatically, dollar volume, deals in which biotechs in-license late-stage products-from other biotechs, or from larger pharmaceutical companies-have spiked over the past two years.
The International Coalition of Medicines Regulatory Authorities have sketched out the criteria that should be met before candidate coronavirus vaccines can proceed into late-stage trials, and agreed on how to design the studies and who should be included.